BOT

5.48%

34.5¢ botanix pharmaceuticals ltd

Ann: Phase 2a Study Shows BTX 1801 Eradicates S. Aureus, page-862

First 862 Last

Share
Profile

Follow
polenta2018

765 Posts.

146

10/02/21

22:53

Post #: 50877958
Share

Originally posted by bigfella195: ↑

When the 1801 results were announced I was pleased that the primary endpoints had been achieved but was left with a few questions. I popped off an email to Botanix and this morning was able to get some answers. They could not have been any more open and forth coming, very appreciative. Thought I would share some insights:

- All 66 participants completed the trial. The participants were tested 3 times prior to the trial to determine if they had Staph Aureus. If they did not have a staph infection on the third test their data was not included and hence the percentages (A post yesterday clarified the calculations).

- There was no data collected at the end of day 5 as the trial was set up around the protocols of trials completed for other nasal decolonization products.

- 2 participants had MRSA, too few to be considered statistically significant. 1 in the vehicle group and 1 in the ointment group. The MRSA in the vehicle group was not eliminated, while the MRSA in the ointment group was successfully eliminated. Botanix had hoped there would be more MRSA cases.

- Side effects were really very mild, a little crustiness in some cases.

- The ASX no longer allow pharmaceutical companies to present comparisons with other company’s trials in announcements.

- The level of nasal staph was coded as eliminated, light, moderate or high. Data about staph levels in participants who were not classified as eliminated is still to come through.

- Participants who were recolognised by staph had there staph treated again and the staph was, in all cases, still susceptible suggesting no resistance development.

- In terms of recolognisation, staph is carried on many parts of the body and persistent carriers recolognize a lot. Other nasal decolonization studies gave participants full body chlorhexadine washes prior to the trial, something that was not done in Botanix’s trial.

- More data about the 1801 trial is still to come in.

-Matt Callaghan will be presenting remotely at a conference next week and hopefully will provide more data about the trial.

It is clear to me that Botanix genuinely believe the data is very good and compares well to competitors in the staph decolonization space, dialysis is one area they think this has some real potential.

My doubts about the results, based on some basic Google searches of other trials, were completely allayed. IMO Botanix is on to something and I’m not selling any time soon. Look forward to Matt’s presentation next week.

Expand

Thanks for that. Got the feeling the next ann might be the kicker. Second bite chance.

BOT Price at posting: 15.0¢ Sentiment: Buy Disclosure: Held
12 Upvote

0 Great analysis

Reply

Top Stories

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

CMX

ChemX Materials kicks off first stage works at WA high purity alumina pilot

LU7

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

Microcap Wrap: 5 explorers with news out today

SS1

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

LRV

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

RCE

Recce's R327 found effective against E.coli during clinical trial

SVL

Silver Mines models five new calderas close to 396Moz Bowdens deposit

AVA

Ava Risk Group expands US presence with A$0.7M Substation Deal

There are more pages in this discussion • 139 more messages in this thread...

First 862 Last

Add BOT (ASX) to my watchlist

(20min delay)
Last 34.5¢		Change -0.020(5.48%)		Mkt cap ! $543.4M

Open	High	Low	Value	Volume
35.5¢	35.5¢	34.0¢	$4.566M	13.13M

Buyers (Bids)

No.	Vol.	Price($)
11	410003	34.5¢

Sellers (Offers)

Price($)	Vol.	No.
35.0¢	346713	8

View Market Depth

No.	Vol.	Price($)
9	403003	0.345
16	304864	0.340
12	887560	0.335
25	2286069	0.330
5	853843	0.325

Price($)	Vol.	No.
0.350	346713	8
0.355	48198	4
0.360	261992	7
0.365	522058	4
0.370	319527	7

Last trade - 16.10pm 28/06/2024 (20 minute delay)

BOT (ASX) Chart

Ann: Phase 2a Study Shows BTX 1801 Eradicates S. Aureus, page-862

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

ChemX Materials kicks off first stage works at WA high purity alumina pilot

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

Microcap Wrap: 5 explorers with news out today

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

Recce's R327 found effective against E.coli during clinical trial

Silver Mines models five new calderas close to 396Moz Bowdens deposit

Ava Risk Group expands US presence with A$0.7M Substation Deal

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Phase 2a Study Shows BTX 1801 Eradicates S. Aureus, page-862

Top Stories

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

ChemX Materials kicks off first stage works at WA high purity alumina pilot

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

Microcap Wrap: 5 explorers with news out today

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

Recce's R327 found effective against E.coli during clinical trial

Silver Mines models five new calderas close to 396Moz Bowdens deposit

Ava Risk Group expands US presence with A$0.7M Substation Deal

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News